Regardless of the size of your organization or how mature your compliance program is, we all face the same challenge — the ability to identify and mitigate risk. As businesses get more complex, enforcement risks continue to increase. Does your compliance program have the ability to proactively identify and manage those risks?
Listen as MediSpend’s VP of Compliance Solutions, Diana Borges, discusses the Department of Justice’s (DOJ) 2019 evaluation of corporate compliance programs.
To learn more, please provide us your information to access the webinar “Overview of the DOJ’s 2019 Evaluation of Corporate Compliance Programs Guidance”. In this webinar, Diana will examine how the DOJ’s recent guidance and the use of metrics can help manage compliance risks in life sciences organizations.
About MediSpend
MediSpend is a global technology company providing best-in-class solutions that enable life science companies to compliantly manage high-risk business functions through top-rated software and client services. MediSpend is the compliance system of record for some of the world’s largest pharmaceutical, medical device, dental and emerging biotech companies around the world. The MediSpend Global Compliance Suite represents the industry’s first global SaaS solution purpose-built to manage the end-to-end process of HCP engagement through transparency reporting, which includes software that facilitates external grant requests. MediSpend is headquartered in Portsmouth, N.H., with offices in Minnesota, New York, Pennsylvania and the Netherlands.